KOSDAQBiotech & Pharma388870

Pharos iBio

₩6,020▼ 1.95%2026-10-02 close

Market Cap

₩77.9B

Turnover

₩300M

Volume

50,000 shares

Shares out.

13M

PER

—

PBR

6.8×

EPS

-₩733

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Pipeline Expansion Amid Losses, Licensing Deals in Focus

The company is broadening its pipeline around lasmotinib and PHI-501, but continues to face zero revenue since listing and a regulatory capital-loss threshold challenge.

1
2025 operating loss narrowed to KRW 11.51 billion from KRW 12.60 billion in 2024, but revenue has remained at zero for four straight years
2
A KRW 19 billion convertible bond issued in December 2025 pushed the debt ratio from 5.5% in 2024 to 114.5% in 2025
3
A joint R&D contract for PHI-701, a 4th-generation EGFR inhibitor, was signed with Kolon Pharma in September 2026, widening external pipeline collaboration
4
Lasmotinib (PHI-101) has secured orphan drug designations from the FDA, EMA, and Korea's MFDS, and is reportedly approaching entry into a global Phase 2 trial
5
With the technology-listing grace period for capital-loss regulation now over, the risk of an administrative-issue designation has come into focus

Business structure

Pharos iBio is a research-focused drug development company that uses its self-developed AI platform, Chemiverse, to discover oncology drug candidates, with licensing-out (L/O) as its primary revenue model.

Its core pipeline asset is lasmotinib (PHI-101), an acute myeloid leukemia (AML) treatment that has completed global Phase 1 trials in Korea and Australia.

The second key asset, PHI-501, targets solid tumors carrying BRAF, KRAS, and NRAS mutations, including colorectal cancer and melanoma, and entered a domestic Phase 1 trial in January 2026.

The company is also expanding PHI-501's indications into refractory lung and colorectal cancers using its DeepRECOM indication-expansion module.

Follow-on pipeline assets include next-generation menin inhibitor PHI-601 and 4th-generation EGFR inhibitor PHI-701; PHI-601 is under joint research with CAPS Bio as part of a Korea Drug Development Fund (KDDF) national project, while PHI-701 is being co-developed with Kolon Pharma's new drug division under a contract spanning candidate discovery through clinical development.

An earlier oncology asset, PHI-201, was licensed to Yuhan Corporation in 2022, but that agreement was terminated in August 2025. The company generated small service revenue between 2019 and 2022, but has recorded zero revenue since 2023 as it concentrated resources on large pipeline clinical programs.

It listed on KOSDAQ in July 2023 under the technology special-listing track, and has recently joined Eli Lilly's AI/ML collaboration platform, Lilly TuneLab, expanding the global applicability of Chemiverse.

Earnings trend

Quarterly revenue · Operating profit

-₩2.4B25Q2-₩3B25Q3-₩2.9B25Q4-₩2.4B26Q1-₩2.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩300M-₩10.6B2022₩0-₩10.1B2023-₩12.6B2024-₩11.5B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	—	-₩2.4B	—
2025Q3	—	-₩3B	—
2025Q4	—	-₩2.9B	—
2026Q1	—	-₩2.4B	—
2026Q2	—	-₩2.3B	—

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩300M	-₩10.6B	-₩16.9B	−3539.8%	−95.5%	6.0%
2023	₩0	-₩10.1B	-₩8.9B	—	−31.5%	4.7%
2024	—	-₩12.6B	-₩10.4B	—	−55.6%	5.5%
2025	—	-₩11.5B	-₩10.7B	—	−76.8%	114.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

In 2025, consolidated operating loss came to KRW 11.51 billion, a modest improvement from KRW 12.60 billion in 2024, while net loss attributable to owners was KRW 10.70 billion, broadly similar to KRW 10.35 billion in 2024.

In 2023 the operating loss was smaller at KRW 10.12 billion with a net loss of KRW 8.92 billion, whereas 2022 saw a much larger net loss of KRW 16.87 billion, indicating meaningful year-to-year volatility.

On a quarterly basis, operating losses widened from KRW 2.43 billion in Q2 2025 to KRW 2.99 billion in Q3 and KRW 2.94 billion in Q4, before narrowing again to KRW 2.37 billion in Q1 2026 and KRW 2.28 billion in Q2 2026.

Over the most recent four quarters (Q3 2025 through Q2 2026), the cumulative net loss attributable to owners was KRW 9.43 billion, implying an average quarterly loss in the low-to-mid KRW 2 billion range.

Cash flow from operations remained negative every year from 2022 to 2025, ranging between roughly KRW 7.4 billion and KRW 9.3 billion in outflows annually, reflecting a research-driven cash-burn structure.

Shareholders' equity shrank each year, from KRW 28.35 billion in 2023 to KRW 18.61 billion in 2024 and KRW 13.93 billion in 2025, reflecting accumulated losses.

In contrast, total liabilities jumped from KRW 1.01 billion in 2024 to KRW 15.94 billion in 2025, driven by the KRW 19 billion convertible bond issued in December 2025, which also pushed the debt ratio sharply higher from 5.5% to 114.5%.

That convertible bond appears intended both to fund lasmotinib development and to provide a future avenue for capital reinforcement through equity conversion.

Industry analysis

The AI-driven drug discovery industry continues to attract partnership interest from global pharmaceutical companies on expectations of shortened candidate-discovery timelines and lower costs, with open collaboration platforms such as Eli Lilly's Lilly TuneLab serving as a notable example.

Many Korean biotech companies list via the technology special-listing track and operate with no revenue while focused on R&D, making licensing-out (L/O) achievements the key validation metric for their business models.

Pharos iBio has not secured a new licensing agreement since its listing, and even its existing PHI-201 agreement with Yuhan Corporation was terminated, extending its revenue gap.

KOSDAQ grants technology-listed companies a three-year grace period from capital-loss-based administrative-issue designation, but afterward, companies that record a capital-loss ratio exceeding 50% of equity in two or more of the prior three years can be designated, a regulatory issue facing numerous biotech companies.

Pharos iBio's 2024 capital-loss ratio already exceeded that threshold at 56.7% of equity, and industry observers are watching whether future profit and capital trends will bring this regulatory risk to bear.

In the oncology space, global pharma companies including Johnson & Johnson are reportedly active in developing menin inhibitor and FLT3 inhibitor combination therapies, and Pharos iBio has positioned its strategy around enhancing lasmotinib's value in line with this combination-therapy trend.

Outlook

The company has positioned 2026 as its 'year of tangible results,' focusing on raising the technical and commercial value of its core pipeline assets.

Lasmotinib demonstrated a 50% composite complete remission (CRc) rate in a Phase 1b trial among relapsed/refractory AML patients, and as of June 2026 was reportedly approaching entry into a global Phase 2 trial.

Research presented at the American Association for Cancer Research (AACR) in April 2026 showed that combining lasmotinib with Johnson & Johnson's menin inhibitor bleximenib maintained tumor growth inhibition of 82-89% even two weeks after treatment discontinuation.

PHI-501 began dosing its first patient in a domestic Phase 1 trial in January 2026, with business development discussions expected to progress depending on early results.

PHI-601 is being developed with CAPS Bio through a national drug development project running through March 2028, aiming to derive lead compounds that overcome acquired resistance, while PHI-701 saw its collaboration scope with Kolon Pharma expand in September 2026 through a joint R&D contract covering candidate discovery through clinical development.

On the financial side, the KRW 19 billion convertible bond issued in December 2025 becomes convertible into equity starting December 19, 2026, and the extent of conversion could affect the company's capital structure and capital-loss ratio going forward.

The company is also consulting with local contract research organizations (CROs) to expand its push for conditional marketing approval of lasmotinib beyond Korea into Japan.

Valuation

PER

—

PBR

6.8×

ROE

-83.2%

EPS

-₩733

BPS

₩755

Dividend per share

₩0

The company has posted net losses for four consecutive quarters, placing it in a loss-making segment where conventional earnings-based valuation metrics are difficult to apply.

Its price-to-book ratio trades at a level reflecting a considerable premium over shrinking shareholders' equity each year, which can be interpreted as the market partially pricing in expectations for future commercialization outcomes such as licensing deals.

No dividend is paid, so dividend-related metrics carry little relevance. Following the largest net loss in 2022, losses have fluctuated within a relatively more contained range from 2023 through 2025, though a clear turn toward profitability has not yet materialized.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Pipeline Diversification and Expanding External Collaboration

Beyond lasmotinib and PHI-501, the company is broadening its pipeline with PHI-601 (with CAPS Bio) and PHI-701 (with Kolon Pharma), reducing dependence on a single asset.

The September 2026 joint R&D contract for PHI-701 with Kolon Pharma marks a progression to a substantive collaboration stage following a May MOU and a June selection for a government-backed project. Selection for Korea Drug Development Fund (KDDF) projects has also helped spread R&D costs using government funding.

Regulatory and Clinical Progress for Lasmotinib

Lasmotinib has secured orphan drug designations from the FDA, EMA, and Korea's MFDS, and recorded a 50% composite complete remission rate in a Phase 1b trial among relapsed/refractory AML patients.

Combination with Johnson & Johnson's menin inhibitor also showed meaningful tumor growth inhibition, opening possibilities for combination therapy expansion.

As of June 2026 the asset was reportedly approaching entry into a global Phase 2 trial, alongside parallel efforts to pursue conditional approval in both Korea and Japan.

Securing R&D Continuity Through External Financing

The KRW 19 billion convertible bond issued in December 2025 secured operating funds needed to develop core pipeline assets including lasmotinib. It represented the company's first major external fundraising in the three years since listing, providing resources to support continuity of R&D activity.

Should the bond be converted into equity in the future, it could also help reinforce total shareholders' equity.

Bear factors

Zero Revenue for Four Consecutive Years

Revenue was zero from 2023 through 2025, and the existing PHI-201 licensing agreement with Yuhan Corporation was terminated in August 2025. The licensing revenue anticipated at the time of listing has yet to materialize. With the timing of any new L/O agreement uncertain, the revenue gap persists.

Administrative-Issue Designation Risk from Capital-Loss Regulation

The three-year grace period from capital-loss regulation under the technology-listing track ended at the close of 2025, and the 2024 capital-loss ratio already exceeded the threshold at 56.7% of equity.

If this threshold is exceeded twice or more over the following three years, the company could be designated an administrative issue, a regulatory risk that is compounded by shrinking equity each year. The company itself has stated it is reviewing capital strategies to improve its financial structure.

Ongoing Cash Burn and Potential Dilution

Operating cash flow was negative every year from 2022 to 2025, ranging roughly from KRW 7.4 billion to KRW 9.3 billion in annual outflows, reflecting continued reliance on external financing to cover R&D costs.

The convertible bond issued in December 2025 becomes convertible starting December 19, 2026, creating potential for share dilution as the share count could increase. Should further capital raises be required, existing shareholders could face additional dilution.

Risk factors

Regulatory Risk

With the capital-loss-based administrative-issue grace period for technology-listed companies now over, a capital-loss ratio exceeding 50% of equity in two or more of the next three years could trigger such a designation.

The threshold was already exceeded in 2024, raising the possibility this risk could materialize with another occurrence. Without capital reinforcement or revenue generation, this risk is difficult to resolve.

Clinical and Development Risk

PHI-501 and PHI-701 are respectively in early Phase 1 trials and candidate discovery stages, requiring multiple further clinical steps before commercialization.

The menin inhibitor, FLT3 inhibitor, and EGFR inhibitor fields are highly competitive areas where global pharmaceutical majors are also actively developing assets. Clinical delays or underwhelming results could weaken the company's negotiating position in licensing discussions.

Financial Risk

With no revenue, the company continues to post annual operating losses and cash outflows of around KRW 10 billion, resulting in heavy reliance on external fundraising.

The debt ratio rose sharply following the 2025 convertible bond issuance, and further capital raises or changes in capital structure from bond conversion may be unavoidable going forward. A deterioration in fundraising conditions could also affect the R&D timeline.

What to watch next

Mid-November 2026
Check the Q3 2026 earnings disclosure to see whether the operating loss and cash-burn pace improve or worsen relative to the recent quarterly trend (KRW 2.28 billion in Q2 2026).
Around December 19, 2026
Watch the start of the conversion window for the KRW 19 billion convertible bond, and assess how much conversion actually occurs and its effect on total equity and the capital-loss ratio.
Second half of 2026
Monitor concrete progress on follow-on pipeline assets, including candidate selection and preclinical entry for PHI-701 (co-developed with Kolon Pharma) and progress on the PHI-601 national project.
Within 2026
Track whether lasmotinib (PHI-101) receives IND approval and actually enters a global Phase 2 trial, along with progress on conditional approval efforts in Korea and Japan.
Disclosures from Q4 2026 onward
Check exchange and company disclosures regarding the official determination of the fiscal 2025 capital-loss ratio and whether an administrative-issue designation is applied.

Overall view

Pharos iBio continues to advance its clinical pipeline centered on lasmotinib and PHI-501, and is in a phase of expanding its pipeline and partnership network through joint research with Kolon Pharma and CAPS Bio and participation in Lilly TuneLab.

However, revenue has remained at zero since 2023, and the December 2025 issuance of a KRW 19 billion convertible bond brought a notable shift in financial structure, sharply raising the debt ratio.

With the capital-loss grace period granted to technology-listed companies now expired, the regulatory risk of a potential administrative-issue designation has also come into focus.

Annual operating losses have fluctuated in the low-to-mid KRW 10 billion range without major improvement or deterioration, and the recent quarterly trend shows a modest narrowing.

Going forward, lasmotinib's entry into a global Phase 2 trial, early clinical results for PHI-501, and whether a new licensing agreement is secured are likely to be the key variables in gauging commercialization progress.

On the financial side, whether the convertible bond converts into equity and the trajectory of the capital-loss ratio will be important indicators for assessing the stability of the capital structure.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.